glp-1 cardiovascular outcomes news today and mortality with receptor agonists vs other glucose-lowering drugs in individuals with NAFLD and type 2 diabetes: a large population-based matched cohort study | Diabetologia Association of GLP-1 inhibitors with

The accumulated evidence over recent decades regarding the efficacy of new pharmacological treatments for obesity has positioned the glucagon-like peptide-1 (GLP-1) analogue as a key componentwhether as monoagonists, unimolecular multiagonists, or in combination therapies targeting multiple receptors.1 These drugs have made it possible to achieve previously unthinkable goals in terms of weight reduction and control of various obesity-related comorbidities (Fig

This isn't just a new drug

The trade-off: its answers come from a model rather than deterministic analysis of your logs, and there is no stall or wear-off detection

PD patients exhibit reduced energy metabolism due to mitochondrial dysfunction, which leads to decreased dopamine synthesis and increased oxidative stress

Due to its peculiar pharmacokinetic characteristics that allow a good efficacy on glycemic and body weight control with a single weekly dose, semaglutide can represent the possibility of killing two (or more) birds with one stone, targeting both diabetes and psoriasis but also obesity

Every pharmaceutical company out there has the capacity to make something like GLP1, and they are doing exactly that